260 related articles for article (PubMed ID: 30793900)
1. Combinatorial Synthesis to Identify a Potent, Necrosis-Inducing Rhenium Anticancer Agent.
Konkankit CC; Vaughn BA; MacMillan SN; Boros E; Wilson JJ
Inorg Chem; 2019 Mar; 58(6):3895-3909. PubMed ID: 30793900
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Anticancer Activity and in Vivo Biodistribution of Rhenium(I) Tricarbonyl Aqua Complexes.
Knopf KM; Murphy BL; MacMillan SN; Baskin JM; Barr MP; Boros E; Wilson JJ
J Am Chem Soc; 2017 Oct; 139(40):14302-14314. PubMed ID: 28948792
[TBL] [Abstract][Full Text] [Related]
3. Photoactivated in Vitro Anticancer Activity of Rhenium(I) Tricarbonyl Complexes Bearing Water-Soluble Phosphines.
Marker SC; MacMillan SN; Zipfel WR; Li Z; Ford PC; Wilson JJ
Inorg Chem; 2018 Feb; 57(3):1311-1331. PubMed ID: 29323880
[TBL] [Abstract][Full Text] [Related]
4. Exploring the In Vivo and In Vitro Anticancer Activity of Rhenium Isonitrile Complexes.
Marker SC; King AP; Granja S; Vaughn B; Woods JJ; Boros E; Wilson JJ
Inorg Chem; 2020 Jul; 59(14):10285-10303. PubMed ID: 32633531
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, characterization and biological evaluation of (99m)Tc/Re-tricarbonyl quinolone complexes.
Kydonaki TE; Tsoukas E; Mendes F; Hatzidimitriou AG; Paulo A; Papadopoulou LC; Papagiannopoulou D; Psomas G
J Inorg Biochem; 2016 Jul; 160():94-105. PubMed ID: 26795497
[TBL] [Abstract][Full Text] [Related]
6. Exploring Ovarian Cancer Cell Resistance to Rhenium Anticancer Complexes.
Marker SC; King AP; Swanda RV; Vaughn B; Boros E; Qian SB; Wilson JJ
Angew Chem Int Ed Engl; 2020 Aug; 59(32):13391-13400. PubMed ID: 32396709
[TBL] [Abstract][Full Text] [Related]
7. Systematically altering the lipophilicity of rhenium(I) tricarbonyl anticancer agents to tune the rate at which they induce cell death.
Konkankit CC; Vaughn BA; Huang Z; Boros E; Wilson JJ
Dalton Trans; 2020 Nov; 49(45):16062-16066. PubMed ID: 32319485
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxicity, cellular localization and photophysical properties of Re(I) tricarbonyl complexes bound to cysteine and its derivatives.
Capper MS; Enriquez Garcia A; Macia N; Lai B; Lin JB; Nomura M; Alihosseinzadeh A; Ponnurangam S; Heyne B; Shemanko CS; Jalilehvand F
J Biol Inorg Chem; 2020 Aug; 25(5):759-776. PubMed ID: 32583226
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Re and (99m)Tc complexes of 2-(4'-aminophenyl)benzothiazole as potential breast cancer radiopharmaceuticals.
Tzanopoulou S; Sagnou M; Paravatou-Petsotas M; Gourni E; Loudos G; Xanthopoulos S; Lafkas D; Kiaris H; Varvarigou A; Pirmettis IC; Papadopoulos M; Pelecanou M
J Med Chem; 2010 Jun; 53(12):4633-41. PubMed ID: 20518489
[TBL] [Abstract][Full Text] [Related]
10. Combining imaging and anticancer properties with new heterobimetallic Pt(ii)/M(i) (M = Re,
Quental L; Raposinho P; Mendes F; Santos I; Navarro-Ranninger C; Alvarez-Valdes A; Huang H; Chao H; Rubbiani R; Gasser G; Quiroga AG; Paulo A
Dalton Trans; 2017 Oct; 46(42):14523-14536. PubMed ID: 28164201
[TBL] [Abstract][Full Text] [Related]
11. Necrosis-Inducing High-Valent Oxo-Rhenium(V) Complexes with Potent Antitumor Activity: Synthesis, Aquation Chemistry, Cisplatin Cross-Resistance Profile, and Mechanism of Action.
Das S; Joshi P; Patra M
Inorg Chem; 2023 Dec; 62(48):19720-19733. PubMed ID: 37974075
[TBL] [Abstract][Full Text] [Related]
12. Aquation and Anation Kinetics of Rhenium(I) Dicarbonyl Complexes: Relation to Cell Toxicity and Bioavailability.
Schutte-Smith M; Marker SC; Wilson JJ; Visser HG
Inorg Chem; 2020 Nov; 59(21):15888-15897. PubMed ID: 33084304
[TBL] [Abstract][Full Text] [Related]
13. Mono- and Dinuclear Phosphorescent Rhenium(I) Complexes: Impact of Subcellular Localization on Anticancer Mechanisms.
Ye RR; Tan CP; Chen MH; Hao L; Ji LN; Mao ZW
Chemistry; 2016 Jun; 22(23):7800-9. PubMed ID: 27106876
[TBL] [Abstract][Full Text] [Related]
14. Dinuclear phosphorescent rhenium(I) complexes as potential anticancer and photodynamic therapy agents.
Pan ZY; Cai DH; He L
Dalton Trans; 2020 Aug; 49(33):11583-11590. PubMed ID: 32766642
[TBL] [Abstract][Full Text] [Related]
15. Neutral rhenium(I) tricarbonyl complexes with sulfur-donor ligands: anti-proliferative activity and cellular localization.
Levina A; Wardhani K; Stephens LJ; Werrett MV; Caporale C; Dallerba E; Blair VL; Massi M; Lay PA; Andrews PC
Dalton Trans; 2024 May; 53(18):7866-7879. PubMed ID: 38632950
[TBL] [Abstract][Full Text] [Related]
16. Design of Rhenium Compounds in Targeted Anticancer Therapeutics.
Collery P; Desmaele D; Vijaykumar V
Curr Pharm Des; 2019; 25(31):3306-3322. PubMed ID: 31475892
[TBL] [Abstract][Full Text] [Related]
17. Highly potent half-sandwich iridium and ruthenium complexes as lysosome-targeted imaging and anticancer agents.
Li J; Tian Z; Xu Z; Zhang S; Feng Y; Zhang L; Liu Z
Dalton Trans; 2018 Nov; 47(44):15772-15782. PubMed ID: 30357192
[TBL] [Abstract][Full Text] [Related]
18. Emissive behavior, cytotoxic activity, cellular uptake, and PEGylation properties of new luminescent rhenium(I) polypyridine poly(ethylene glycol) complexes.
Choi AW; Louie MW; Li SP; Liu HW; Chan BT; Lam TC; Lin AC; Cheng SH; Lo KK
Inorg Chem; 2012 Dec; 51(24):13289-302. PubMed ID: 23198846
[TBL] [Abstract][Full Text] [Related]
19. X-Ray fluorescence microscopy reveals that rhenium(i) tricarbonyl isonitrile complexes remain intact in vitro.
Konkankit CC; Lovett J; Harris HH; Wilson JJ
Chem Commun (Camb); 2020 Jun; 56(48):6515-6518. PubMed ID: 32432584
[TBL] [Abstract][Full Text] [Related]
20. The rhenium(I)-diselenoether anticancer drug targets ROS, TGF-β1, VEGF-A, and IGF-1 in an in vitro experimental model of triple-negative breast cancers.
Collery P; Veena V; Harikrishnan A; Desmaele D
Invest New Drugs; 2019 Oct; 37(5):973-983. PubMed ID: 30632005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
